BNF:

8.3.4.2

Status:

Do Not Prescribe (DNP), Red

Decision Date:

August 2014

Comments

RED^1,2,3: NICE TA316: enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with docetaxel-containing regimen.

RED^1,2,3: NICE TA377  - for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. (Decision date - February 2016)

RED^1,2,3: NICE TA712 - for treating hormone-sensitive metastatic prostate cancer (Decision date - August 2021)

DO NOT PRESCRIBE -

DNP: NICE TA580 - for hormone-relapsed non-metastatic prostate cancer. (Decision date  - June 2019)

DNP: NICE TA994 (Terminated Appraisal): Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (Decision date - September 2024)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again